These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 31254921)

  • 41. Design, synthesis, and biological evaluation of N-(pyridin-3-yl)pyrimidin-4-amine analogues as novel cyclin-dependent kinase 2 inhibitors for cancer therapy.
    Zeng WB; Ji TY; Zhang YT; Ma YF; Li R; You WW; Zhao PL
    Bioorg Chem; 2024 Feb; 143():107019. PubMed ID: 38096683
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
    Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
    Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
    Roy T; Boateng ST; Banang-Mbeumi S; Singh PK; Basnet P; Chamcheu RN; Ladu F; Chauvin I; Spiegelman VS; Hill RA; Kousoulas KG; Nagalo BM; Walker AL; Fotie J; Murru S; Sechi M; Chamcheu JC
    Bioorg Chem; 2021 Feb; 107():104595. PubMed ID: 33450548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
    Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
    Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploring new quinazolin-4(3H)-one derivatives as CDK2 inhibitors: Design, synthesis, and anticancer evaluation.
    Ibrahim BT; Allam HA; El-Dydamony NM; Fouad MA; Mohammed ER
    Drug Dev Res; 2024 Apr; 85(2):e22163. PubMed ID: 38419305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
    Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
    Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and biological evaluation of guanidino analogues of roscovitine.
    Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
    Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of pteridin-7(8H)-one analogues as highly potent cyclin-dependent kinase 4/6 inhibitors: Synthesis, structure-activity relationship, and biological activity.
    Li Q; Chen L; Ma YF; Jian XE; Ji JH; You WW; Zhao PL
    Bioorg Chem; 2021 Nov; 116():105324. PubMed ID: 34509794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
    Metwally NH; Mohamed MS; Ragb EA
    Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model.
    Reddy VG; Reddy TS; Jadala C; Reddy MS; Sultana F; Akunuri R; Bhargava SK; Wlodkowic D; Srihari P; Kamal A
    Eur J Med Chem; 2019 Nov; 182():111609. PubMed ID: 31445229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel pyrazolopyrimidines: Synthesis, in vitro cytotoxic activity and mechanistic investigation.
    Hassan GS; Abdel Rahman DE; Nissan YM; Abdelmajeed EA; Abdelghany TM
    Eur J Med Chem; 2017 Sep; 138():565-576. PubMed ID: 28704759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
    Nan X; Zhang J; Li HJ; Wu R; Fang SB; Zhang ZZ; Wu YC
    Eur J Med Chem; 2020 Aug; 200():112470. PubMed ID: 32505087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel Tetrahydrobenzo [b] Thiophene Compounds Exhibit Anticancer Activity through Enhancing Apoptosis and Inhibiting Tyrosine Kinase.
    El-Metwally SA; Khalil AK; El-Naggar AM; El-Sayed WM
    Anticancer Agents Med Chem; 2018; 18(12):1761-1769. PubMed ID: 30101717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis and molecular modeling study of certain 4-Methylbenzenesulfonamides with CDK2 inhibitory activity as anticancer and radio-sensitizing agents.
    Ghorab MM; Ragab FA; Heiba HI; Elsayed MSA; Ghorab WM
    Bioorg Chem; 2018 Oct; 80():276-287. PubMed ID: 29966874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Scaffold Hopping Approach to a New Series of Pyridine Derivatives as Potent Inhibitors of CDK2.
    Xu X; Yao Q
    Arch Pharm (Weinheim); 2016 Mar; 349(3):224-31. PubMed ID: 26871934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents.
    Ma J; Bao G; Wang L; Li W; Xu B; Du B; Lv J; Zhai X; Gong P
    Eur J Med Chem; 2015; 96():173-86. PubMed ID: 25874341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
    Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.